Balyasny Asset Management
WST icon

Balyasny Asset Management’s West Pharmaceutical WST Stock Holding History

Balyasny Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,000
Closed -$4.67M – 2477
2021
Q2 		$4.67M Buy
+13,000
New +$4.3M 0.02% 737

Other funds holding WST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's WST Position: Q1 2026 in Review

Balyasny Asset Management reduced its West Pharmaceutical (WST) stake by 4.6% in Q1 2026, selling an estimated $13.4K and leaving 1,121 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #2582.

Balyasny Asset Management first reported a position in WST in Q4 2016 and has held it in 22 quarters since. The position peaked at $77.7M in Q3 2023. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Balyasny Asset Management held 1,121 shares of West Pharmaceutical worth $281K as of Q1 2026.
  • Balyasny Asset Management sold 54 West Pharmaceutical shares in Q1 2026, an estimated $13.4K.
  • West Pharmaceutical made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2582 holding.
  • Balyasny Asset Management first reported a position in West Pharmaceutical in Q4 2016 and has held it in 22 quarters since.
  • Balyasny Asset Management's West Pharmaceutical position peaked at $77.7M in Q3 2023.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.